The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants

3Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The world's first coronavirus disease 2019 human challenge trial using the D614G strain of severe acute respiratory syndrome 2 (SARS-CoV-2) is underway in the United Kingdom. The Wellcome Trust is funding challenge stock preparation of the Beta and Delta variant for a follow-up human challenge trial, and researchers at hVIVO are considering conducting these trials. However, little has been written thus far about the ethical justifiability of human challenge trials with SARS-CoV-2 variants of concern. We explore 2 specific characteristics of some variants that may initially be thought to make such trials unethical and conclude that SARS-CoV-2 variant challenge trials can remain ethical.

Cite

CITATION STYLE

APA

Rohrig, A., & Eyal, N. (2022). The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants. Journal of Infectious Diseases, 225(6), 934–937. https://doi.org/10.1093/infdis/jiab488

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free